Interpace Announces Additional Job Cuts as Part of Restructuring

https://www.genomeweb.com/molecular-diagnostics/interpace-announces-additional-job-cuts-part-restructuring


Interpace Diagnostics announced today that it has cut 18 employees as part of an ongoing effort to restructure itself into a pure-play molecular diagnostics firm.


The move, the company said, will result in about $11.5 million in annual cost savings. 


In November, Interpace — formerly known as PDI — disclosed that it was selling off its biomedical commercialization and marketing services business in order to focus on its molecular diagnostic offerings, which include the ThyGenX genetic mutation panel and its soon-to-be-launched ThyraMir microRNA expression classifier. A month later, the firm trimmed 36 staffers, primarily from its commercial services segment.